Regulators worldwide are intensifying oversight mechanisms across pharmaceuticals, cannabis, clinical trials, and emerging therapies. The FDA is rolling out new inspection protocols and foreign manufacturing requirements while governments expand monitoring of health data and advanced therapies like gene and stem cell treatments.
·FDA proposes mandatory registration and product listing for foreign pharmaceutical manufacturers
·Illinois strengthens cannabis industry oversight with new equity-focused regulations
·FDA pilots one-day inspection model to streamline facility compliance checks
·Real-time clinical trial monitoring systems shift oversight from endpoint-based to continuous assessment
·U.S. and India both expand central licensing authority over emerging biotechnology sectors
drawn from regulatoryoversight.com, CBS News, The Regulatory Review, Applied Clinical Trials Online · updated 6h ago